Autoantibodies targeting AT1 receptor from patients with acute coronary syndrome upregulate proinflammatory cytokines expression in endothelial cells involving NF-κB pathway

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Li, Weijuan ^a   Li, Zhi ^a   Chen, Yaoqi ^a   Li, Songhai ^a   Lv, Yuanyuan ^a   Zhou, Wenping ^a   Liao, Mengyang ^a   Zhu, Feng ^a   Zhou, Zihua ^a   Cheng, Xiang ^a   Zeng, Qiutang ^a   Liao, Yuhua ^a   Wei, Yumiao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; C REACTIVE PROTEIN; CREATININE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PYRROLIDINE DITHIOCARBAMATE; SYNAPTOTAGMIN I; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTACOID; AUTOANTIGEN; PEPTIDE FRAGMENT; PROLINE; PROLINEDITHIOCARBAMATE; THIOCARBAMIC ACID DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ANIMAL CELL; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL CULTURE; CHRONOTROPISM; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; PEPTIDE SYNTHESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; ENDOTHELIUM CELL; GENETICS; IMMUNOLOGY; METABOLISM; RAT; SYNTHESIS;

ACUTE CORONARY SYNDROME; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; CELLS, CULTURED; CHEMOKINE CCL2; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MYOCYTES, CARDIAC; NF-KAPPA B; PEPTIDE FRAGMENTS; PROLINE; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; THIOCARBAMATES; VALSARTAN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84918581582     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/342693     Document Type: Article

References (49)

1. M. L. X. Fu, H. Herlitz, W. Schulze et al., "Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension," Journal of Hypertension, vol. 18, no. 7, pp. 945-953, 2000.
2. Y.-H. Liao, Y.-M. Wei, M. Wang, Z.-H. Wang, H.-T. Yuan, and L.-X. Cheng, "Autoantibodies against AT1-receptor and α1- adrenergic receptor in patients with hypertension," Hypertension Research, vol. 25, no. 4, pp. 641-646, 2002.
3. G. Wallukat, V. Homuth, T. Fischer et al., "Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor," The Journal of Clinical Investigation, vol. 103, no. 7, pp. 945-952, 1999.
4. R. Dechend, D. N. Müller, G. Wallukat et al., "Activating autoantibodies against the AT1 receptor in preeclampsia," Autoimmunity Reviews, vol. 4, no. 1, pp. 61-65, 2005.
5. D. Dragun, D. N. Müller, J. H. Bräsen et al., "Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection," The New England Journal of Medicine, vol. 352, no. 6, pp. 558-569, 2005.
6. 2+ mobilization in cultured rat vascular smooth muscle cells," Cellular and Molecular Immunology, vol. 5, no. 3, pp. 209-217, 2008.
7. B.Wang, Y.-H. Liao, Z. Zhou et al., "Arterial structural changes in rats immunized by AT1-receptor peptide," Heart and Vessels, vol. 20, no. 4, pp. 153-158, 2005.
8. 1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase," Circulation, vol. 107, no. 12, pp. 1632-1639, 2003.
9. K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, "NAD(P)H oxidase: role in cardiovascular biology and disease," Circulation Research, vol. 86, no. 5, pp. 494-501, 2000.
10. E.Matsuura, K. Kobayashi, Y.Matsunami et al., "Autoimmunity, infectious immunity, and atherosclerosis," Journal of Clinical Immunology, vol. 29, no. 6, pp. 714-721, 2009.
11. G. K. Hansson, "Mechanisms of disease: Inflammation, atherosclerosis, and coronary artery disease," The New England Journal of Medicine, vol. 352, no. 16, pp. 1626-1695, 2005.
12. D. S. Jacoby and D. J. Rader, "Renin-angiotensin system and atherothrombotic disease: from genes to treatment," Archives of Internal Medicine, vol. 163, no. 10, pp. 1155-1164, 2003.
13. C. Marchesi, P. Paradis, and E. L. Schiffrin, "Role of the renin-angiotensin system in vascular inflammation," Trends in Pharmacological Sciences, vol. 29, no. 7, pp. 367-374, 2008.
14. C. Rius, M. Abu-Taha, C. Hermenegildo et al., "Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-κB activation and peroxisome proliferator-activated receptor-γ upregulation," Journal of Immunology, vol. 185, no. 6, pp. 3718-3727, 2010.
15. X. C. Li and J. L. Zhuo, "Nuclear factor-κB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury," Current Opinion in Nephrology and Hypertension, vol. 17, no. 1, pp. 37-43, 2008.
16. S. E. Nissen, E. M. Tuzcu, P. Schoenhagen et al., "Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial," Journal of the American Medical Association, vol. 291, no. 9, pp. 1071-1080, 2004.
17. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, and G. Di Sciascio, "Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction ofMYocardial Damage during Angioplasty) study," Circulation, vol. 110, no. 6, pp. 674-678, 2004.
18. L. Oliveira, C. M. Costa-Neto, C. R. Nakaie, S. Schreier, S. I. Shimuta, and A. C. M. Paiva, "The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure," Physiological Reviews, vol. 87, no. 2, pp. 565-592, 2007.
19. G. Wallukat, S. Podlowski, E. Nissen et al., "Functional and structural characterization of anti-β1-adrenoceptor autoantibodies of spontaneously hypertensive rats," Molecular and Cellular Biochemistry, vol. 251, no. 1-2, pp. 67-75, 2003.
20. H. P. Wang, W. H. Zhang, X. F. Wang et al., "Exposure to AT1 receptor autoantibodies during pregnancy increases susceptibility of the maternal heart to postpartum ischemia-reperfusion injury in rats," International Journal of Molecular Science, vol. 15, no. 7, pp. 11495-11509, 2014.
21. R. Dechend, V. Homuth, G. Wallukat et al., "AT1 receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor," Circulation, vol. 101, no. 20, pp. 2382-2387, 2000.
22. G. Wallukat, D. Neichel, E. Nissen, V. Homuth, and F. C. Luft, "Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia," Canadian Journal of Physiology and Pharmacology, vol. 81, no. 2, pp. 79-83, 2003.
23. X. Ren, H. Shao, Q. Wei, Z. Sun, and N. Liu, "Advanced glycation end-products enhance calcification in vascular smooth muscle cells," The Journal of International Medical Research, vol. 37, no. 3, pp. 847-854, 2009.
24. R.-Y. Zhang, Y.-Y. Liu, L. Li et al., "Increased levels of soluble vascular endothelial cadherin are associated with poor outcome in severe sepsis," Journal of International Medical Research, vol. 38, no. 4, pp. 1497-1506, 2010.
25. M. Li, J. Lin, Z. Wang, S. He, X. Ma, and D. Li, "Oxidized low-density lipoprotein-induced proinflammatory cytokine response inmacrophages are suppressed by CD4CD25+Foxp3+ regulatory T cells through downregulating toll like receptor 2-mediated activation of NF-κB," Cellular Physiology and Biochemistry, vol. 25, no. 6, pp. 649-656, 2010.
26. Z. Jin, W. Zhang, W. Chai, Y. Zheng, and J. Zhi, "Antibodies against AT1 receptors are associated with vascular endothelial and smooth," PloS ONE, vol. 8, no. 6,Article ID e67020, 2013.
27. T. Chardès, N. Chapal, D. Bresson et al., "The human antithyroid peroxidase autoantibody repertoire in Graves' and Hashimoto's autoimmune thyroid diseases," Immunogenetics, vol. 54, no. 3, pp. 141-157, 2002.
28. M. L. X. Fu, H. Herlitz, G. Wallukat et al., "Functional autoimmune epitope on α1-adrenergic receptors in patients with malignant hypertension," The Lancet, vol. 344, no. 8938, pp. 1660-1663, 1994.
29. K.Wenzel, H. Haase, G. Wallukat et al., "Potential relevance of α1-Adrenergic receptor autoantibodies in refractory hypertension," PLoS ONE, vol. 3, no. 11,Article ID e3742, 2008.
30. Z. Zhou, Y.-H. Liao, Y. Wei et al., "Cardiac remodeling after long-term stimulation by antibodies against the α 1-adrenergic receptor in rats," Clinical Immunology, vol. 114, no. 2, pp. 164- 173, 2005.
31. R. Jahns, V. Boivin, L. Hein et al., "Direct evidence for a β1- adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy," Journal of Clinical Investigation, vol. 113, no. 10, pp. 1419-1429, 2004.
32. G. Wallukat, S. G. M. Saravia, A. Haberland et al., "Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients," Journal of the American College of Cardiology, vol. 55, no. 5, pp. 463-468, 2010.
33. G. Wallukat, J. Müller, and R. Hetzer, "Specific removal of β1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy," The New England Journal of Medicine, vol. 347, no. 22, p. 1806, 2002.
34. S. B. Felix, A. Staudt, M. Landsberger et al., "Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption," Journal of the American College of Cardiology, vol. 39, no. 4, pp. 646-652, 2002.
35. J. Müller, G. Wallukat, M. Dandel et al., "Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy," Circulation, vol. 101, no. 4, pp. 385-391, 2000.
36. P. Libby, "Inflammation and cardiovascular disease mechanisms1-3," The American Journal of Clinical Nutrition, vol. 83, no. 2, pp. 456S-460S, 2006.
37. R. G. Baker, M. S. Hayden, and S. Ghosh, "NF-κB, inflammation, and metabolic disease," Cell Metabolism, vol. 13, no. 1, pp. 11-22, 2011.
38. M. Guo, X. Mao, Q. Ji et al., "Inhibition of IFN regulatory factor-1 down-regulate Th1 cell function in patients with acute coronary syndrome," Journal of Clinical Immunology, vol. 30,no. 2, pp. 241-252, 2010.
39. X. Cheng, Y.-H. Liao, H. Ge et al., "Th1/Th2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation," Journal of Clinical Immunology, vol. 25, no. 3, pp. 246-253, 2005.
40. P. Libby, P. M. Ridker, and G. K. Hansson, "Progress and challenges in translating the biology of atherosclerosis," Nature, vol. 473, no. 7347, pp. 317-325, 2011.
41. S. Yusuf and P. Sleight, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients," The New England Journal of Medicine, vol. 342, no. 3, pp. 145-153, 2000.
42. M. Sata and D. Fukuda, "Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis," The Journal of Medical Investigation, vol. 57, no. 1-2, pp. 12-25, 2010.
43. 2 in vascular smooth muscle cells molecularmechanisms," Circulation Research, vol. 86,no. 12,pp. 1266-1272, 2000.
44. M. S. Hayden and S. Ghosh, "Signaling to NF-κB," Genes and Development, vol. 18, no. 18, pp. 2195-2224, 2004.
45. 1 receptor: novel insights intomechanisms and pathophysiology," Clinical Science, vol. 112, no. 7-8, pp. 417-428, 2007.
46. B. Halvorsen, K. Otterdal, T. B. Dahl et al., "Atherosclerotic plaque stability-what determines the fate of a plaque?" Progress in Cardiovascular Diseases, vol. 51, no. 3, pp. 183-194, 2008.
47. B. Schieffer, E. Schieffer, D. Hilfiker-Kleiner et al., "Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability," Circulation, vol. 101, no. 12, pp. 1372- 1378, 2000.
48. G. Stoll and M. Bendszus, "Inflammation and atherosclerosis: novel insights into plaque formation and destabilization," Stroke, vol. 37, no. 7, pp. 1923-1932, 2006.
49. H. Stepan, G. Wallukat, H.-P. Schultheiss, R. Faber, and T. Walther, "Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor?" Journal of Reproductive Immunology, vol. 73, no. 2, pp. 130-134, 2007.